Showing 31-40 of 235 results for "".
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel Pharmaceuticals Limited. Independent Data Safety Monitoring Board stated…
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe plaque psoriasis. These new results were presented at the 22nd Congress of the Europe…
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A392111…
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 …
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III can also be used in a wide range of other body shaping applications such as cellulite treatments. "In…
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials…
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or photothera…
EHR User Series—Part III
https://practicaldermatology.com/topics/practice-management/ehr-user-seriespart-iii/21509/A Q&A series with clinicians about their experience and broader impressions of EHRs in dermatology.Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
https://practicaldermatology.com/programs/cme/prosecution-argument-for-brafmek-targeted-adjuvant-treatment-of-stage-iii-melanoma/15906/tbdPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investig